DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Herbst RS, Tsuboi M, John T. et al.
Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.
Poster Abstract Congress of the American Society of Clinical Oncology Journal (ASCO). 2020 38(18_suppl): LBA5-LBA5
Access:
We do not assume any responsibility for the contents of the web pages of other providers.